Abstract
Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-β interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.
Current Enzyme Inhibition
Title: Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Volume: 6 Issue: 2
Author(s): Hai-Chun Yang, Yiqin Zuo and Agnes B. Fogo
Affiliation:
Keywords: TGF-β, kidney, fibrosis
Abstract: Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-β interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.
Export Options
About this article
Cite this article as:
Yang Hai-Chun, Zuo Yiqin and B. Fogo Agnes, Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?, Current Enzyme Inhibition 2010; 6 (2) . https://dx.doi.org/10.2174/157340810791233042
DOI https://dx.doi.org/10.2174/157340810791233042 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolic Syndrome Targets
Current Drug Targets - CNS & Neurological Disorders Ambulatory Blood Pressure and Diabetes: Targeting Nondipping
Current Diabetes Reviews Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis
Current Pharmaceutical Design Insulin Therapy for Improving Cardiac Surgical Outcomes
Current Drug Targets Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research The Transcriptional Regulation of the Human CYP2C Genes
Current Drug Metabolism Solvent-Free Synthesis of 1,3-Diphenyl-5-arylpyrazole Derivatives
Letters in Organic Chemistry Mediterranean Diet in Predementia and Dementia Syndromes
Current Alzheimer Research Incretin-Based Therapies in Patients with Type 2 Diabetes
Current Drug Therapy Long-Term Exposure to Ambient Hydrocarbons Increases Dementia Risk in People Aged 50 Years and above in Taiwan
Current Alzheimer Research Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews Resveratrol as a Supplemental Therapeutic in Cardiovascular and Metabolic Syndromes: A Critical Review
Current Nutrition & Food Science Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention
Current Drug Targets Novel Therapeutic Targets for Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Current Vascular Pharmacology Diterpenes: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery The Role of Spiritual Health Experience with Intensity and Duration of Labor Pain While Childbearing and Postpartum
Current Women`s Health Reviews Challenges in Vascular Repair by Endothelial Progenitor Cells in Diabetic Patients
Cardiovascular & Hematological Disorders-Drug Targets